Go Pro
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free XLO Stock Alerts

Xilio Therapeutics (XLO) Financials

Xilio Therapeutics logo
$8.98 -0.05 (-0.50%)
As of 03:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Xilio Therapeutics

Annual Income Statements for Xilio Therapeutics

This table shows Xilio Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -55 -76 -88 -76 -58 -35
Consolidated Net Income / (Loss)		 -55 -76 -88 -76 -58 -35
Net Income / (Loss) Continuing Operations		 -55 -76 -88 -76 -58 -35
Total Pre-Tax Income 		-55 -76 -88 -79 -58 -35
Total Operating Income		 -55 -75 -89 -79 -61 -42
Total Gross Profit		 0.00 0.00 0.00 0.00 6.34 44
Total Revenue		 0.00 0.00 0.00 0.00 6.34 44
Operating Revenue		 - - - 0.00 6.34 44
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 55 75 89 79 67 86
Selling, General & Admin Expense		 11 24 30 27 25 30
Research & Development Expense		 44 51 59 52 41 56
Restructuring Charge		 - - - 0.00 0.94 0.00
Total Other Income / (Expense), net		 -0.66 -0.76 0.93 0.00 2.34 6.95
Other Income / (Expense), net		 -0.66 -0.76 0.93 - 2.34 6.95
Basic Earnings per Share		 ($105.42) ($13.52) ($3.22) ($2.78) ($15.24) ($4.19)
Weighted Average Basic Shares Outstanding		 523.79K 5.61M 27.39M 27.50M 3.82M 8.36M
Diluted Earnings per Share		 ($105.42) ($13.52) ($3.22) ($2.78) ($15.24) ($4.19)
Weighted Average Diluted Shares Outstanding		 523.79K 5.61M 27.47M 27.50M 3.82M 8.36M
Weighted Average Basic & Diluted Shares Outstanding		 - 27.47M 27.47M 34.47M 51.77M 5.78M

Quarterly Income Statements for Xilio Therapeutics

This table shows Xilio Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -17 -18 -17 -14 -14 -13 -13 -16 -0.91 -5.02 -9.53
Consolidated Net Income / (Loss)		 -17 -18 -17 -14 -14 -13 -13 -16 -0.91 -5.02 -9.53
Net Income / (Loss) Continuing Operations		 -17 -18 -17 -14 -14 -13 -13 -16 -0.91 -5.02 -9.53
Total Pre-Tax Income 		-17 -20 -17 -14 -14 -13 -13 -16 -0.91 -5.02 -9.53
Total Operating Income		 -17 -18 -17 -15 -15 -14 -14 -14 -1.93 -12 -14
Total Gross Profit		 0.00 - 0.00 2.36 2.26 1.72 2.93 8.08 19 14 13
Total Revenue		 0.00 - 0.00 2.36 2.26 1.72 2.93 8.08 19 14 13
Operating Revenue		 0.00 - 0.00 2.36 2.26 1.72 2.93 8.08 19 14 13
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 17 18 17 17 17 15 17 22 21 26 27
Selling, General & Admin Expense		 6.31 6.39 6.14 5.82 6.31 6.52 8.52 7.12 6.67 7.40 6.93
Research & Development Expense		 11 12 10 11 11 8.84 8.27 15 14 18 20
Restructuring Charge		 0.00 - 0.95 0.03 -0.04 - 0.00 0.00 0.00 - 0.00
Total Other Income / (Expense), net		 0.61 -2.25 0.28 0.78 0.74 0.54 0.59 -1.48 1.02 6.82 4.58
Other Income / (Expense), net		 0.61 - 0.28 0.78 0.74 0.54 0.59 -1.48 1.02 6.82 4.58
Basic Earnings per Share		 ($0.61) ($0.64) ($0.62) ($0.24) ($0.22) ($3.43) ($2.49) ($0.16) ($0.11) ($0.60) ($0.58)
Weighted Average Basic Shares Outstanding		 27.52M 27.50M 27.91M 57.76M 63.47M 3.82M 5.34M 96.45M 144.11M 8.36M 16.35M
Diluted Earnings per Share		 ($0.61) ($0.64) ($0.62) ($0.24) ($0.22) ($3.43) ($2.49) ($0.16) ($0.11) ($0.60) ($0.58)
Weighted Average Diluted Shares Outstanding		 27.52M 27.50M 27.91M 57.76M 63.47M 3.82M 5.34M 96.45M 144.11M 8.36M 16.35M

Annual Cash Flow Statements for Xilio Therapeutics

This table details how cash moves in and out of Xilio Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -28 179 -78 -76 11 82
Net Cash From Operating Activities		 -36 -81 -76 -69 -18 -4.99
Net Cash From Continuing Operating Activities		 -36 -81 -76 -69 -18 -4.99
Net Income / (Loss) Continuing Operations		 -55 -76 -88 -76 -58 -35
Consolidated Net Income / (Loss)		 -55 -76 -88 -76 -58 -35
Depreciation Expense		 1.07 1.50 1.85 1.90 1.64 1.54
Non-Cash Adjustments To Reconcile Net Income		 1.76 5.69 9.04 8.00 6.44 3.38
Changes in Operating Assets and Liabilities, net		 16 -12 1.61 -2.12 32 25
Net Cash From Investing Activities		 -2.19 -1.10 -1.87 -0.49 -0.04 -0.52
Net Cash From Continuing Investing Activities		 -2.19 -1.10 -1.87 -0.49 -0.04 -0.52
Purchase of Property, Plant & Equipment		 -2.19 -1.10 -1.87 -0.49 -0.04 -0.52
Net Cash From Financing Activities		 10 261 -0.07 -6.55 29 88
Net Cash From Continuing Financing Activities		 10 261 -0.07 -6.55 29 88
Repayment of Debt		 0.00 -1.00 0.00 -6.67 -3.33 0.00
Issuance of Common Equity		 0.00 116 0.00 0.19 33 88
Other Financing Activities, net		 0.06 -0.55 -0.07 -0.08 -0.04 0.01
Cash Interest Paid		 0.54 0.49 0.56 0.57 0.06 0.00

Quarterly Cash Flow Statements for Xilio Therapeutics

This table details how cash moves in and out of Xilio Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -16 -15 -9.55 40 -14 -5.96 34 32 -18 34 13
Net Cash From Operating Activities		 -13 -13 -11 20 -14 -14 29 -14 -17 -2.00 -22
Net Cash From Continuing Operating Activities		 -13 -13 -11 20 -14 -14 29 -14 -17 -2.00 -22
Net Income / (Loss) Continuing Operations		 -17 -18 -17 -14 -14 -13 -13 -16 -16 10 -9.53
Consolidated Net Income / (Loss)		 -17 -18 -17 -14 -14 -13 -13 -16 -16 10 -9.53
Depreciation Expense		 0.46 0.45 0.44 0.45 0.38 0.38 0.50 0.38 0.34 0.32 0.34
Non-Cash Adjustments To Reconcile Net Income		 2.00 2.07 1.96 1.38 1.57 1.52 1.54 3.54 17 -18 -1.09
Changes in Operating Assets and Liabilities, net		 0.92 1.71 4.30 32 -1.61 -2.96 40 -2.55 -18 5.66 -12
Net Cash From Investing Activities		 - - 0.00 -0.02 -0.01 -0.01 -0.02 -0.40 - -0.10 -0.56
Net Cash From Continuing Investing Activities		 - - 0.00 -0.02 -0.01 -0.01 -0.02 -0.40 - -0.10 -0.56
Purchase of Property, Plant & Equipment		 - - 0.00 -0.02 -0.01 -0.01 -0.02 -0.40 - -0.10 -0.56
Net Cash From Financing Activities		 -2.24 -1.63 0.95 20 -0.00 8.20 4.83 47 -0.29 36 36
Net Cash From Continuing Financing Activities		 -2.24 -1.63 0.95 20 -0.00 8.20 4.83 47 -0.29 36 36
Repayment of Debt		 -2.22 -1.67 -3.33 - - - 0.00 - - - 0.00
Repurchase of Common Equity		 - - - - - - 0.00 - - - -1.55
Issuance of Common Equity		 - 0.05 4.31 20 - 8.20 4.83 47 -0.29 36 37
Other Financing Activities, net		 -0.01 -0.02 -0.02 -0.02 -0.00 - 0.01 0.00 - 0.00 0.00
Cash Interest Paid		 0.14 0.10 0.06 - - - 0.00 - - - 0.00

Annual Balance Sheets for Xilio Therapeutics

This table presents Xilio Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 36 218 139 61 71 155
Total Current Assets		 21 203 124 48 60 145
Cash & Equivalents		 19 198 120 45 55 138
Prepaid Expenses		 1.35 4.46 4.11 3.42 4.94 2.50
Other Current Assets		 - - - - 0.00 5.00
Plant, Property, & Equipment, net		 0.00 7.62 7.26 5.94 4.47 3.89
Total Noncurrent Assets		 16 7.92 7.41 6.86 6.37 5.77
Other Noncurrent Operating Assets		 16 7.92 7.41 6.86 6.37 5.77
Total Liabilities & Shareholders' Equity		 36 218 139 61 71 155
Total Liabilities		 42 33 34 24 53 119
Total Current Liabilities		 22 13 21 16 27 56
Accounts Payable		 5.44 3.14 3.13 1.05 2.57 3.17
Accrued Expenses		 14 8.75 10 10 9.98 12
Current Deferred Revenue		 - - - 0.00 14 40
Other Current Liabilities		 0.65 0.88 1.00 1.10 1.19 1.34
Total Noncurrent Liabilities		 19 20 12 8.14 26 63
Noncurrent Deferred Revenue		 - - - 0.00 19 21
Other Noncurrent Operating Liabilities		 12 10 9.23 8.14 6.95 43
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -83 185 106 37 18 35
Total Preferred & Common Equity		 -83 185 106 37 18 35
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -83 185 106 37 18 35
Common Stock		 1.80 346 355 362 401 454
Retained Earnings		 -85 -161 -249 -326 -384 -419

Quarterly Balance Sheets for Xilio Therapeutics

This table presents Xilio Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 78 83 90 75 104 134 134 163
Total Current Assets		 64 69 78 63 93 124 124 154
Cash & Equivalents		 60 34 75 61 89 122 104 150
Prepaid Expenses		 4.71 5.21 3.06 2.05 4.13 2.17 2.83 3.87
Other Current Assets		 - - - - - - 18 0.00
Plant, Property, & Equipment, net		 6.37 5.54 5.14 4.85 4.29 4.02 3.68 3.68
Total Noncurrent Assets		 7.00 7.88 6.73 6.50 6.23 6.08 5.93 5.60
Other Noncurrent Operating Assets		 7.00 7.88 6.73 6.50 6.23 6.08 5.93 5.60
Total Liabilities & Shareholders' Equity		 78 83 90 75 104 134 134 163
Total Liabilities		 25 57 56 54 93 127 142 91
Total Current Liabilities		 17 32 39 38 48 53 56 43
Accounts Payable		 1.49 0.75 1.26 0.97 2.28 4.10 2.30 1.06
Accrued Expenses		 9.40 8.00 9.74 9.79 3.88 5.62 8.95 8.97
Current Deferred Revenue		 - 22 27 26 40 42 44 32
Other Current Liabilities		 1.08 1.11 1.12 1.15 1.23 1.26 1.30 1.38
Total Noncurrent Liabilities		 8.42 25 18 16 45 73 85 48
Noncurrent Deferred Revenue		 - 17 10 8.40 39 29 25 16
Other Noncurrent Operating Liabilities		 8.42 7.86 7.57 7.26 6.64 45 60 32
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 52 26 33 21 11 7.07 -8.10 73
Total Preferred & Common Equity		 52 26 33 21 11 7.07 -8.10 73
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 52 26 33 21 11 7.07 -8.10 73
Common Stock		 360 368 390 392 408 420 421 501
Retained Earnings		 -308 -343 -357 -371 -397 -413 -429 -428

Annual Metrics And Ratios for Xilio Therapeutics

This table displays calculated financial ratios and metrics derived from Xilio Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 27,468,948.00 27,471,607.00 27,542,000.00 43,958,074.00 52,500,328.00
DEI Adjusted Shares Outstanding		 0.00 27,468,948.00 27,471,607.00 27,542,000.00 3,139,862.00 3,750,023.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -2.76 -3.21 -2.77 -18.55 -9.34
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 589.88%
EBITDA Growth		 0.00% -37.20% -16.25% 10.58% 26.72% 40.82%
EBIT Growth		 0.00% -37.27% -16.39% 10.30% 26.40% 39.84%
NOPAT Growth		 0.00% -37.54% -18.80% 11.24% 23.44% 30.70%
Net Income Growth		 0.00% -37.27% -16.39% 13.40% 23.77% 39.84%
EPS Growth		 0.00% 87.18% 76.18% 13.66% 23.77% 39.84%
Operating Cash Flow Growth		 0.00% -123.74% 6.23% 9.38% 73.22% 72.84%
Free Cash Flow Firm Growth		 0.00% 0.00% 5.94% 7.86% 83.36% 479.22%
Invested Capital Growth		 0.00% 79.73% -63.75% 7.01% -726.24% -171.29%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 37.32% 37.61%
EBITDA Q/Q Growth		 0.00% 0.00% -3.09% 2.58% 10.68% 20.59%
EBIT Q/Q Growth		 0.00% 0.00% -3.14% 2.56% 10.51% 19.96%
NOPAT Q/Q Growth		 0.00% 0.00% -4.22% 5.98% 6.92% 4.10%
Net Income Q/Q Growth		 0.00% 0.00% -3.24% 5.92% 7.26% 18.73%
EPS Q/Q Growth		 0.00% 0.00% -105.33% 6.08% 7.26% 18.73%
Operating Cash Flow Q/Q Growth		 0.00% -5.84% -1.42% 6.53% -4.14% 70.89%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 6.58% -22.22% -14.06%
Invested Capital Q/Q Growth		 0.00% 0.00% -60.12% -96.89% 6.43% 8.58%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -892.13% -76.53%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -954.95% -95.92%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -918.05% -80.05%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -918.05% -80.05%
Tax Burden Percent		 100.00% 100.00% 100.00% 96.55% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 1,044.83% -84.15% -60.62% -107.25% -214.02% -132.53%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -88.24% -31.04%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -88.24% -31.04%
Return on Common Equity (ROCE)		 16,465.53% -47.72% -60.62% -107.25% -214.02% -132.53%
Return on Equity Simple (ROE_SIMPLE)		 66.30% -40.88% -83.51% -207.47% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -38 -53 -62 -55 -42 -29
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -668.46% -67.15%
Net Nonoperating Expense Percent (NNEP)		 -179.34% -23.51% -17.27% -27.66% -32.75% -5.86%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -137.99% -240.98% -83.31%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 390.57% 67.88%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 649.61% 128.04%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 1,054.95% 195.92%
Earnings before Interest and Taxes (EBIT)		 -55 -76 -88 -79 -58 -35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -54 -74 -86 -77 -57 -33
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.37 0.70 0.41 2.39 0.95
Price to Tangible Book Value (P/TBV)		 0.00 2.37 0.70 0.41 2.39 0.95
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 6.62 0.77
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 -1.84 0.05 0.09 0.09 0.00 0.00
Long-Term Debt to Equity		 -1.40 0.05 0.03 0.00 0.00 0.00
Financial Leverage		 1.80 -1.10 -1.03 -1.07 -1.78 -3.65
Leverage Ratio		 -6.87 1.41 1.23 1.40 2.43 4.27
Compound Leverage Factor		 -6.87 1.41 1.23 1.40 2.43 4.27
Debt to Total Capital		 218.50% 4.94% 8.51% 8.26% 0.00% 0.00%
Short-Term Debt to Total Capital		 52.31% 0.00% 5.77% 8.26% 0.00% 0.00%
Long-Term Debt to Total Capital		 166.19% 4.94% 2.74% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 1,748.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -1,867.42% 95.06% 91.49% 91.74% 100.00% 100.00%
Debt to EBITDA		 -0.18 -0.13 -0.11 -0.04 0.00 0.00
Net Debt to EBITDA		 0.18 2.54 1.28 0.54 0.00 0.00
Long-Term Debt to EBITDA		 -0.14 -0.13 -0.04 0.00 0.00 0.00
Debt to NOPAT		 -0.26 -0.18 -0.16 -0.06 0.00 0.00
Net Debt to NOPAT		 0.25 3.59 1.77 0.75 0.00 0.00
Long-Term Debt to NOPAT		 -0.19 -0.18 -0.05 0.00 0.00 0.00
Altman Z-Score		 -6.65 6.95 -2.38 -10.76 -9.15 -3.40
Noncontrolling Interest Sharing Ratio		 -1,475.91% 43.30% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.93 15.85 5.90 3.02 2.21 2.58
Quick Ratio		 0.87 15.50 5.70 2.80 2.03 2.44
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -64 -60 -56 -9.28 35
Operating Cash Flow to CapEx		 -1,649.50% -7,341.00% -4,055.87% -14,119.34% -51,050.00% -963.71%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.10 0.39
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 1.22 10.47
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -15 -3.00 -4.91 -4.56 -38 -102
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.30 -0.63
Increase / (Decrease) in Invested Capital		 0.00 12 -1.91 0.34 -33 -65
Enterprise Value (EV)		 186 251 -37 -26 -13 -104
Market Capitalization		 118 440 74 15 42 34
Book Value per Share		 ($159.01) $6.75 $3.85 $1.34 $0.40 $0.67
Tangible Book Value per Share		 ($159.01) $6.75 $3.85 $1.34 $0.40 $0.67
Total Capital		 4.46 195 115 40 18 35
Total Debt		 9.75 9.63 9.83 3.32 0.00 0.00
Total Long-Term Debt		 7.41 9.63 3.17 0.00 0.00 0.00
Net Debt		 -9.49 -188 -111 -41 -55 -138
Capital Expenditures (CapEx)		 2.19 1.10 1.87 0.49 0.04 0.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -18 -8.31 -10 -9.22 -22 -49
Debt-free Net Working Capital (DFNWC)		 0.77 190 110 35 33 89
Net Working Capital (NWC)		 -1.57 190 103 32 33 89
Net Nonoperating Expense (NNE)		 17 23 26 21 16 5.65
Net Nonoperating Obligations (NNO)		 -9.49 -188 -111 -41 -55 -138
Total Depreciation and Amortization (D&A)		 1.07 1.50 1.85 1.90 1.64 1.54
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -351.80% -111.45%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 519.75% 202.79%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 519.75% 202.79%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($13.52) ($3.22) ($2.78) ($15.26) ($4.19)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 5.61M 27.39M 27.50M 3.82M 8.36M
Adjusted Diluted Earnings per Share		 $0.00 ($13.52) ($3.22) ($2.78) ($15.26) ($4.19)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 5.61M 27.39M 34.47M 3.82M 8.36M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 27.47M 27.47M 34.47M 3.70M 5.78M
Normalized Net Operating Profit after Tax (NOPAT)		 -38 -53 -62 -55 -42 -29
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -658.13% -67.15%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -918.05% -80.05%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Xilio Therapeutics

This table displays calculated financial ratios and metrics derived from Xilio Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 27,539,620.00 27,542,000.00 34,473,486.00 36,912,373.00 43,952,491.00 43,958,074.00 51,773,717.00 51,782,273.00 51,827,910.00 52,500,328.00 5,782,511.00
DEI Adjusted Shares Outstanding		 27,539,620.00 27,542,000.00 34,473,486.00 36,912,373.00 43,952,491.00 3,139,862.00 3,698,123.00 51,782,273.00 51,827,910.00 3,750,023.00 5,782,511.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.61 -0.64 -0.50 -0.38 -0.32 -4.17 -3.59 -0.31 -0.02 -1.34 -1.65
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 242.98% 742.51% 693.85% 331.67%
EBITDA Growth		 15.68% 19.55% 24.32% 28.54% 16.26% 28.08% 23.82% -14.71% 95.84% 63.07% 28.06%
EBIT Growth		 15.37% 19.30% 24.04% 28.05% 16.29% 27.78% 22.89% -13.78% 93.53% 61.66% 28.16%
NOPAT Growth		 14.08% 21.74% 25.67% 26.90% 14.97% 24.83% 20.79% 2.30% 86.93% 13.16% -1.88%
Net Income Growth		 15.37% 21.41% 24.04% 28.05% 16.29% 25.84% 22.89% -13.78% 93.53% 61.66% 28.16%
EPS Growth		 15.28% 21.95% 25.30% 65.71% 63.93% 25.84% 22.89% 33.33% 50.00% 61.66% 76.71%
Operating Cash Flow Growth		 32.85% 26.32% 58.41% 220.39% -2.27% -5.44% 375.93% -172.56% -27.96% 85.89% -177.10%
Free Cash Flow Firm Growth		 13.04% 8.89% 75.29% 262.58% 314.23% 280.98% 1,509.41% 107.03% 154.12% 138.57% -117.31%
Invested Capital Growth		 24.38% 7.01% -3,011.74% -4,723.81% -1,638.67% -726.24% -854.02% -175.64% -177.67% -171.29% 0.75%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -3.99% -23.82% 69.95% 175.90% 135.85% -28.22% -7.58%
EBITDA Q/Q Growth		 13.65% -8.55% 5.21% 19.57% -1.19% 6.77% -0.40% -21.11% 96.33% -728.40% -95.55%
EBIT Q/Q Growth		 13.47% -8.25% 5.11% 19.05% -0.68% 6.61% -1.31% -19.44% 94.28% -453.47% -89.82%
NOPAT Q/Q Growth		 13.70% -4.43% 3.55% 15.91% -0.39% 7.68% -1.63% -3.72% 86.57% -513.58% -19.23%
Net Income Q/Q Growth		 13.47% -5.42% 2.56% 19.05% -0.68% 6.61% -1.31% -19.44% 94.28% -453.47% -89.82%
EPS Q/Q Growth		 12.86% -4.92% 3.13% 61.29% 8.33% 6.61% -1.31% 11.11% 31.25% -453.47% 3.33%
Operating Cash Flow Q/Q Growth		 19.34% -0.43% 21.78% 289.99% -168.52% -3.55% 304.69% -149.96% -20.85% 88.58% -1,018.27%
Free Cash Flow Firm Q/Q Growth		 30.97% -1.05% 67.09% 808.16% -9.03% -14.63% 156.30% 4.02% 11.66% -19.86% -118.59%
Invested Capital Q/Q Growth		 -169.11% -96.89% -80.07% -405.58% 3.00% 6.43% -107.92% -46.07% 2.29% 8.58% 23.93%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% -571.91% -602.74% -737.65% -435.77% -191.28% -2.97% -34.32% -72.62%
Operating Margin		 0.00% 0.00% 0.00% -623.84% -652.32% -790.55% -472.73% -177.71% -10.12% -86.48% -111.58%
EBIT Margin		 0.00% 0.00% 0.00% -590.79% -619.53% -759.45% -452.73% -195.99% -4.76% -36.68% -75.34%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -590.79% -619.53% -759.45% -452.73% -195.99% -4.76% -36.68% -75.34%
Tax Burden Percent		 100.00% 86.61% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 112.43% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -90.85% -107.25% -128.37% -130.03% -170.96% -214.02% -297.84% -277.74% -669.45% -132.53% -75.20%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -15.28% -37.54% -73.00% -45.07% -26.29% -1.45% -14.22% -30.16%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -15.28% -37.54% -73.00% -45.07% -26.29% -1.45% -14.22% -30.16%
Return on Common Equity (ROCE)		 -90.85% -107.25% -128.37% -130.03% -170.96% -214.02% -297.84% -277.74% -669.45% -132.53% -75.20%
Return on Equity Simple (ROE_SIMPLE)		 -154.70% 0.00% -275.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -13 -12 -10 -10 -9.54 -9.70 -10 -1.35 -8.29 -9.88
NOPAT Margin		 0.00% 0.00% 0.00% -436.69% -456.62% -553.38% -330.91% -124.40% -7.08% -60.54% -78.10%
Net Nonoperating Expense Percent (NNEP)		 -4.99% -6.53% -8.34% -5.07% -6.35% -7.35% -5.80% -5.89% 0.54% 3.39% 0.29%
Return On Investment Capital (ROIC_SIMPLE)		 - -31.62% -47.51% -30.80% -49.27% -54.21% -90.61% -142.26% 16.68% -23.49% -13.62%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 246.71% 278.70% 378.02% 290.61% 88.08% 35.00% 54.07% 54.78%
R&D to Revenue		 0.00% 0.00% 0.00% 475.86% 475.43% 512.53% 282.12% 189.63% 75.11% 132.41% 156.80%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 723.84% 752.32% 890.55% 572.73% 277.71% 110.12% 186.48% 211.58%
Earnings before Interest and Taxes (EBIT)		 -17 -18 -17 -14 -14 -13 -13 -16 -0.91 -5.02 -9.53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -18 -17 -13 -14 -13 -13 -15 -0.57 -4.70 -9.19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.11 0.41 1.15 1.05 1.65 2.39 3.51 4.98 0.00 0.95 0.67
Price to Tangible Book Value (P/TBV)		 1.11 0.41 1.15 1.05 1.65 2.39 3.51 4.98 0.00 0.95 0.67
Price to Revenue (P/Rev)		 0.00 0.00 0.00 14.84 7.49 6.62 4.04 2.35 1.37 0.77 0.91
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.09 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.07 -1.08 -1.42 -1.58 -1.78 -3.37 -4.85 -12.81 -3.65 -2.88
Leverage Ratio		 1.32 1.40 1.76 1.81 2.08 2.43 5.11 5.53 16.18 4.27 3.21
Compound Leverage Factor		 1.32 1.58 1.76 1.81 2.08 2.43 5.11 5.53 16.18 4.27 3.21
Debt to Total Capital		 8.63% 8.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 8.63% 8.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.37% 91.74% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.06 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.69 0.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.08 -0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.93 0.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -4.14 -7.45 -5.64 -5.14 -6.72 -7.05 -4.92 -3.80 -3.49 -2.76 -2.40
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.81 3.02 2.19 2.02 1.67 2.21 1.96 2.32 2.20 2.58 3.59
Quick Ratio		 3.53 2.80 2.03 1.94 1.61 2.03 1.87 2.28 1.84 2.44 3.50
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -13 -13 -4.29 30 28 24 60 63 70 56 -10
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 95,014.29% -151,911.11% -235,950.00% 131,718.18% -3,610.22% 0.00% -2,103.16% -4,018.53%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.03 0.06 0.10 0.10 0.13 0.31 0.39 0.40
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.40 0.82 1.22 1.89 3.28 7.46 10.47 13.42
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.32 -4.56 -8.22 -42 -40 -38 -78 -114 -112 -102 -78
Invested Capital Turnover		 0.00 0.00 0.00 -0.11 -0.22 -0.30 -0.21 -0.19 -0.42 -0.63 -0.69
Increase / (Decrease) in Invested Capital		 0.75 0.34 -7.95 -41 -38 -33 -70 -73 -72 -65 0.59
Enterprise Value (EV)		 3.29 -26 -4.23 -40 -27 -13 -52 -86 -60 -104 -102
Market Capitalization		 58 15 30 35 35 42 38 35 44 34 49
Book Value per Share		 $1.91 $1.34 $0.94 $0.91 $0.48 $0.40 $0.21 $0.14 ($0.16) $0.67 $12.55
Tangible Book Value per Share		 $1.91 $1.34 $0.94 $0.91 $0.48 $0.40 $0.21 $0.14 ($0.16) $0.67 $12.55
Total Capital		 57 40 26 33 21 18 11 7.07 -8.10 35 73
Total Debt		 4.96 3.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -55 -41 -34 -75 -61 -55 -89 -122 -104 -138 -150
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.02 0.01 0.01 0.02 0.40 0.00 0.10 0.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.26 -9.22 3.62 -36 -36 -22 -44 -51 -36 -49 -39
Debt-free Net Working Capital (DFNWC)		 53 35 38 39 25 33 46 70 68 89 111
Net Working Capital (NWC)		 48 32 38 39 25 33 46 70 68 89 111
Net Nonoperating Expense (NNE)		 4.60 4.96 4.96 3.63 3.69 3.55 3.57 5.79 -0.44 -3.27 -0.35
Net Nonoperating Obligations (NNO)		 -55 -41 -34 -75 -61 -55 -89 -122 -104 -138 -150
Total Depreciation and Amortization (D&A)		 0.46 0.45 0.44 0.45 0.38 0.38 0.50 0.38 0.34 0.32 0.34
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -1,509.63% -778.61% -351.80% -469.16% -340.61% -113.43% -111.45% -73.08%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 1,670.22% 547.34% 519.75% 491.30% 469.68% 212.83% 202.79% 208.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 1,670.22% 547.34% 519.75% 491.30% 469.68% 212.83% 202.79% 208.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.61) ($0.64) ($0.62) ($0.24) ($0.22) ($48.02) ($2.52) ($0.16) ($0.11) ($8.40) ($0.58)
Adjusted Weighted Average Basic Shares Outstanding		 27.52M 27.50M 27.91M 57.76M 63.47M 273.02K 5.34M 96.45M 144.11M 597.08K 16.35M
Adjusted Diluted Earnings per Share		 ($0.61) ($0.64) ($0.62) ($0.24) ($0.22) ($48.02) ($2.52) ($0.16) ($0.11) ($8.40) ($0.58)
Adjusted Weighted Average Diluted Shares Outstanding		 27.52M 27.50M 36.91M 57.76M 63.47M 273.02K 5.34M 96.45M 144.11M 597.08K 16.35M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($48.02) $0.00 $0.00 $0.00 ($8.40) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 27.54M 34.47M 36.91M 43.95M 43.96M 3.70M 3.70M 51.83M 52.50M 413.04K 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -13 -12 -10 -10 -9.54 -9.70 -10 -1.35 -8.29 -9.88
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -435.80% -457.89% -553.38% -330.91% -124.40% -7.08% -60.54% -78.10%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -590.79% -619.53% -759.45% -452.73% -195.99% -4.76% -36.68% -75.34%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Xilio Therapeutics (NASDAQ: XLO) showed a much stronger liquidity position in Q1 2026, but the company is still not generating profits and remains heavily dependent on financing to support operations.

  • Cash & equivalents rose to $150.3 million at March 31, 2026, up from $103.8 million at the end of Q3 2025 and well above year-ago levels.
  • The balance sheet showed $163.5 million in total assets versus $90.9 million in total liabilities, leaving book equity of $72.5 million.
  • Revenue in Q1 2026 was $12.6 million, more than four times the $2.9 million reported in Q1 2025, indicating meaningful top-line growth.
  • Deferred revenue remains significant, with $31.5 million current and $16.5 million noncurrent, which suggests future revenue recognition potential.
  • Other income, net of $4.6 million, helped partially offset operating losses in the quarter.
  • Operating cash flow was still negative at ($22.3 million), reflecting continued cash burn from core operations.
  • Research & development spending of $19.8 million and SG&A of $6.9 million show the company is still investing heavily in its pipeline and overhead.
  • The company added cash in Q1 2026 primarily through financing, including $37.3 million of common equity issuance.
  • Xilio reported a net loss of $9.5 million in Q1 2026, or $0.58 per share, so profitability remains out of reach.
  • Share dilution is a major overhang: weighted average basic shares were 16.3 million in Q1 2026, but prior quarters showed much lower share counts, indicating a substantially expanded share base over the past year.
  • Compared with the prior year, the company is still burning cash, and the business has relied on repeated equity raises to fund operations.

Trend summary: Xilio Therapeutics entered 2026 with a much stronger cash cushion and a healthier balance sheet than it had a year ago, which is a clear positive for near-term survivability. However, the company is still posting operating losses and negative operating cash flow, and its progress has come with meaningful dilution. For retail investors, the key question is whether revenue growth and pipeline execution can eventually outpace ongoing spending before the cash balance starts to decline again.

07/17/26 01:12 PM ETAI Generated. May Contain Errors.

Xilio Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Xilio Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Xilio Therapeutics' net income appears to be on a downward trend, with a most recent value of -$35.04 million in 2025, falling from -$55.22 million in 2020. The previous period was -$58.24 million in 2024. View Xilio Therapeutics' forecast to see where analysts expect Xilio Therapeutics to go next.

Xilio Therapeutics' total operating income in 2025 was -$41.98 million, based on the following breakdown:
  • Total Gross Profit: $43.77 million
  • Total Operating Expenses: $85.75 million

Over the last 5 years, Xilio Therapeutics' total revenue changed from $0.00 in 2020 to $43.77 million in 2025, a change of 4,376,600,000.0%.

Xilio Therapeutics' total liabilities were at $119.41 million at the end of 2025, a 123.3% increase from 2024, and a 187.0% increase since 2020.

In the past 5 years, Xilio Therapeutics' cash and equivalents has ranged from $19.24 million in 2020 to $198.05 million in 2021, and is currently $137.53 million as of their latest financial filing in 2025.

Over the last 5 years, Xilio Therapeutics' book value per share changed from -159.01 in 2020 to 0.67 in 2025, a change of -100.4%.


Related Companies

Financial statements for NASDAQ:XLO last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel